TABLE 4.
Cox Regression for the Association Between Race and DFS, Adjusted for Potential Confounders Determined A Priori
| Univariable | Multivariable | |||
|---|---|---|---|---|
| Parameter | HR (95% CI) | p-value | HR (95% CI) | p-value |
| White race | 0.51 (0.35-0.73) | <0.001 | 0.85 (0.44-1.64) | 0.631 |
| Mode of diagnosis | 0.001 | -- | -- | |
| Mammogram | 1.00 | |||
| Other | 0.49 (0.09-2.57) | |||
| Physical findings | 3.67 (1.82-7.39) | |||
| Insurance | 0.869 | -- | -- | |
| Government | 1.00 | |||
| Commercial/Private | 0.95 (0.5-1.81) | |||
| Tumor size (cm) | 1.57 (1.25-1.98) | <0.001 | 1.25 (0.9-1.74) | 0.177 |
| AJCC Stage | <0.001 | 0.032 | ||
| Stage I | 1.00 | 1.00 | ||
| Stage II | 2.57 (1.4-4.73) | 1.66 (0.37-7.34) | ||
| Stage III | 10.27 (4.02-26.22) | 8.61 (1.03-72.2) | ||
| ER+ | 0.26 (0.13-0.5) | <0.001 | -- | -- |
| PR+ | 0.27 (0.14-0.52) | <0.001 | -- | -- |
| HER2+ | 0.7 (0.35-1.39) | 0.306 | -- | -- |
| Grade (Histological) | 0.001 | -- | -- | |
| 1 | 1.00 | |||
| 2 | 0.45 (0.05-3.66) | |||
| 3 | 5.88 (1.06-32.67) | |||
| Nodal positivity | 3.29 (1.91-5.67) | <0.001 | 0.65 (0.15-2.84) | 0.565 |
| ECE | 3.33 (1.58-7.02) | 0.002 | 1.75 (0.38-7.96) | 0.47 |
| LVI | 2.5 (1.4-4.46) | 0.002 | 1.13 (0.37-3.43) | 0.826 |
| Molecular subtype | 0.001 | 0.002 | ||
| HR+/HER2− | 1.00 | 1.00 | ||
| HR−/HER2+ | 4.99 (2.29-10.89) | 2.56 (0.39-16.63) | ||
| HR−/HER2− | 1.67 (0.49-5.7) | 7.48 (2.21-25.28) | ||
| HR+/HER2+ | 0.76 (0.31-1.88) | 0.71 (0.15-3.28) | ||
| Mastectomy vs BCS | 1.9 (1.11-3.27) | 0.02 | 0.99 (0.4-2.44) | 0.975 |
| Chemotherapy | 7.0 (2.74-17.87) | <0.001 | 1.87 (0.47-7.43) | 0.375 |
Abbreviations: DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; ER, estrogen receptor, ECE, extracapsular extension; LVI, lymphovascular invasion; BCS, breast-conserving surgery